1. Scrip

Jimmy Carter Credits Merck's Keytruda For Cancer-Free Success

 
• By Donna Young

While Bristol-Myers Squibb & Co.'s programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab) is well ahead of Merck & Co.'s competing drug Keytruda (pembrolizumab) in FDA approved indications, it's the latter drug that's likely going to stick in the minds of the American public – at least for the time being.

While Bristol-Myers Squibb & Co.'s programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab) is well ahead of Merck & Co.'s competing drug Keytruda (pembrolizumab) in FDA approved indications, it's the latter drug that's likely going to stick in the minds of the American public – at least for the time being.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas